Concepedia

Paul Jackson

PJ

41

Publications

2.2K

Citations

24

H-Index

1985

Active since

Affiliations

Johnson & Johnson (United States)(Current)

Janssen (United States)

Guilford College

The University of Melbourne

Walter and Eliza Hall Institute of Medical Research

Paul Jackson is an author at Johnson & Johnson (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

1985–2025

41

Publications

41

Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury

Barbara S. Slusher, James J. Vornov, Ajit G. Thomas et al. · Nature Medicine · 1999 · 300 citations

, , +12

Design, Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N-Acetylated α-Linked Acidic Dipeptidase

Paul Jackson, Derek C. Cole, Barbara S. Slusher et al. · Journal of Medicinal Chemistry · 1996 · 251 citations · Full text

Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation

Robert H. Scannevin, Richard Alexander, Tara Mezzasalma Haarlander et al. · Journal of Biological Chemistry · 2017 · 171 citations · Full text

Neuroprotective Effects of Inhibiting Poly(ADP-Ribose) Synthetase on Focal Cerebral Ischemia in Rats

Kazushi Takahashi, Joel Greenberg, Paul Jackson et al. · Journal of Cerebral Blood Flow & Metabolism · 1997 · 157 citations

, , +20

Regioselective Preparation of 2-Substituted 3,4-Diaryl Pyrroles:  A Concise Total Synthesis of Ningalin B

James L. Bullington, Russell R. Wolff, Paul Jackson · The Journal of Organic Chemistry · 2002 · 107 citations

Rows per page

1–5 of 41